Post-Market Requirements Could Broaden Label For Allos' Newly Approved PTCL Drug Folotyn
This article was originally published in The Pink Sheet Daily
Executive Summary
Allos gains its first U.S. indication with the accelerated approval of Folotyn (pralatrexate) in peripheral T-cell lymphoma.
You may also be interested in...
Accelerated Approval: Acrotech’s Confirmatory Trial For Folotyn, Beleodaq More Than A Decade Behind Schedule
Under sponsor's current timetable, a single, two-part trial for pralatrexate and belinostat would not complete until 2030, resulting in respective delays of 21 and 16 years in confirming or refuting clinical benefit following accelerated approval. ODAC will discuss Acrotech’s delayed confirmatory trial program on 16 November.
Spectrum Puts Its Eggs In One Basket: Folotyn, Beleodaq To Share Confirmatory Trial
With Spectrum’s Beleodaq’s accelerated approval for peripheral T-cell lymphoma, FDA rolls Folotyn accelerated approval requirement into one post-marketing trial that will provide answers on both drugs – including which is better against standard of care.
Allos Looks To Boost Lymphoma Drug Folotyn's Prospects With Mundipharma Deal
Currently the only approved drug for relapsed or refractory PTCL in the U.S., Folotyn may soon have competition from Celgene's Istodax.